Alnylam Pharmaceuticals (NASDAQ: ALNY) will present late-breaking clinical data on its transthyretin amyloidosis (ATTR) and hypertension therapies at the European Society of Cardiology Congress 2026 in Munich.
The presentations, scheduled for August 30, will include analyses from the HELIOS-B Phase 3 study of vutrisiran (AMVUTTRA), evaluating treatment outcomes in patients on background stabilizer therapy. Additional HELIOS-B data will examine healthy aging, functional capacity, safety, and treatment outcomes by sex. A real-world analysis from France’s Amylo'ExTTRa database will characterize the multisystem burden of ATTR cardiomyopathy beyond cardiac manifestations.
The company will also present a subgroup analysis from the KARDIA-3 Phase 2 study of zilebesiran, assessing its use in combination with a diuretic in patients with uncontrolled hypertension. Zilebesiran, co-developed with Roche, is under evaluation in the ZENITH Phase 3 cardiovascular outcomes trial.
AMVUTTRA is approved in the EU for treating hereditary transthyretin amyloidosis in adults with stage 1 or 2 polyneuropathy, as well as for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy. The drug is administered once quarterly via subcutaneous injection.
Transthyretin amyloidosis, a rare disease affecting more than 500,000 people globally, is caused by pathogenic transthyretin proteins that form amyloid deposits in tissues. Approximately 80% of cases remain undiagnosed.
